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Abstract
Therapeutic options for patients with metastatic renal cell carcinoma have significantly improved over
the past few years, resulting in prolonged progression-free and overall survival.
Introduction and context
Renal cell carcinoma (RCC) is the sixth leading cause of
cancer deaths in developed nations [1]. Until recently,
immunotherapy with interferon-alpha (IFN-a)a n d
interleukin-2 were the only therapies available for
patients with advanced disease, with major response
rates typically seen in 10-15% of patients. Most patients
died of their disease within 1 to 2 years of developing
metastases. Identification of the VHL (Von Hippel-
Lindau) tumor-suppressor gene and the discovery that
its inactivation in clear cell RCCs leads to increased
expression of hypoxia-inducible factor-alpha (HIF-a)
and angiogenesis related proteins, such as vascular
endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF) B chain, led to the development of
new therapies that specifically target VEGF signaling
pathways. Multiple effective agents are now available
that prolong progression-free survival (PFS) and/or
overall survival in phase III randomized studies. These
agents have become the standard care for most patients.
Recent advances
Bevacizumab, a humanized VEGF-neutralizing antibody,
was the first VEGF-targeted therapy to show activity in
metastatic RCC [2]. Two multicentered phase III studies
compared bevacizumab plus IFN-a to IFN-a alone as
first-line treatment in patients with metastatic RCC [3,4].
Both studies demonstrated a significant improvement
in PFS in patients receiving bevacizumab (10.2 versus
5.4 months and 8.5 versus 5.6 months) as well as an
increase in the objective tumor response rate (30.6%
versus 12.4% and 25.5% versus 13.1%). Based on these
trials, bevacizumab plus IFN-a has recently been
approved by the US Food and Drug Administration
(FDA) for the treatment of metastatic RCC.
Sunitinib is an oral tyrosine kinase-inhibitor that targets
VEGF receptors, PDGF receptors, the Fms-like tyrosine
kinase (FLT)3 and the c-KIT receptor tyrosine kinase.
Sunitinib first demonstrated antitumor activity in
cytokine refractory patients with a median time-to-
progression of 8.7 months [5]. A randomized phase III
trial compared sunitinib with IFN-a in patients with
previously untreated metastatic clear-cell RCC [6]. In this
trial, patients treated with sunitinib demonstrated a 31%
objective response rate and a median PFS and overall
survival of 11 and 26.4 months, respectively, while
patients treated with interferon experienced a 6%
objective response rate, a 5-month median PFS, and a
21.8-month median overall survival [7].
Sorafenib is another multikinase inhibitor designed as a
c-Raf and b-Raf kinase inhibitor, but it also inhibits
VEGF receptors, PDGF receptors, FLT3 and KIT. A phase
III randomized study of sorafenib compared with
placebo for second-line therapy in cytokine-refractory
RCC patients showed that patients receiving sorafenib
had a significantly prolonged median PFS compared
with placebo (24 versus 12 weeks) [8].
A randomized phase II trial of first-line treatment
with sorafenib (400 mg twice daily) compared with
IFN-a for previously untreated patients with clear-cell
RCC demonstrated no significant difference in PFS
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perception that older patients are at higher risk for
toxicity effects and may obtain less clinical benefit from
cancer treatment, sorafenib treatment demonstrated
similar PFS and overall efficacy for both older and
younger patients with advanced RCC. In addition, the
frequency, severity, and quality of life of sorafenib-
related toxicities were similar between the two age
groups [10].
Clinical studies have also successfully targeted rapamy-
cin, a protein kinase responsible for protein translation,
cell growth, and apoptosis. The mammalian target of
rapamycin (mTOR) protein is frequently activated in
RCC, which can result in increased production of HIF-
1a. Two current ester analogues of rapamycin, temsir-
olimus and everolimus, in addition to rapamycin itself,
have shown antitumor activity. A recent phase III trial
evaluating the PFS of orally administered everolimus
versus placebo in patients who progressed on at least one
VEGF-targeted therapy demonstrated a median PFS of
4 months versus 1.9 months in the placebo patient
group [11].
This study was the first phase III randomized trial to
demonstrate efficacy of second-line therapy for patients
who progress on a VEGF inhibitor. Temsirolimus, which
is administered intravenously weekly, was previously
FDA-approved based on the results of a randomized trial
of temsirolimus and IFN-a in patients with poor risk
RCC, with a median overall survival of 10.9 months in
patients receiving the mTOR inhibitor compared with
7.3 months for patients receiving IFN-a alone [12].
Implications for clinical practice
The therapeutic options for patients with metastatic RCC
have greatly increased with the development of drugs
targeting the VEGF and mTOR pathways. Variability in
trial design and eligibility criteria for the multiple studies
can make it difficult to compare results and to determine
if one agent is superior as first- or second-line therapy.
Furthermore, differences in the clinical effects and
toxicities of these agents as well as characteristics of
individual patients may affect a physician’s choice of
therapy. There are currently potentially many different
treatment approaches for each patient with metastatic
RCC with the universal goal of prolonging survival
[13,14]. Several clinical trials designed to determine if a
specific combination or sequence of agents is superior
have recently been opened. These include the BeST trial
(ECOG E2804), which is a randomized phase II study of
various combinations of bevacizumab, sorafenib and
temsirolimus in patients with advanced RCC. In addi-
tion, the ASSURE trial (Adjuvant Sorafenib or Sunitinib
for Unfavorable Renal Carcinoma) is designed to
determine if adjuvant therapy has a role in patients
who have undergone nephrectomy. Unfortunately, the
results of these studies are unlikely to be available for a
number of years.
Abbreviations
ASSURE, Adjuvant Sorafenib or Sunitinib for Unfavor-
able Renal Carcinoma; FDA, US Food and Drug
Administration; FLT3, Fms-like tyrosine kinase 3; HIF,
hypoxia-inducible factor; IFN-a,i n t e r f e r o na l p h a ;
mTOR, mammalian target of rapamycin; PDGF, plate-
let-derived growth factor receptor; PFS, progression free
survival; RCC, renal cell carcinoma; VEGF, vascular
endothelial growth factor; VHL, Von Hippel-Lindau.
Competing interests
The authors declare that they have no competing
interests.
References
1. Patel PH, Chaganti RS, Motzer RJ: Targeted therapy for
metastatic renal cell carcinoma. Br J Cancer 2006, 94:614-9.
2. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ,
Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized
trial of bevacizumab, an anti-vascular endothelial growth
factor antibody, for metastatic renal cancer. N Engl J Med 2003,
349:427-34.
3. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S,
Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V,
Bay J, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus
interferon alfa-2a for treatment of metastatic renal cell
carcinoma: a randomised, double-blind phase III trial. Lancet
2007, 370:2103-11.
F1000 Factor 4.8 Must Read
Evaluated by David M Nanus 02 May 2008, Shahrokh Shariat 16 Jun
2008
4. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou S,
Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ:
Bevacizumab plus interferon alfa compared with interferon
alfa monotherapy in patients with metastatic renal cell
carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-8.
5. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G,
Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ,
Bello CL, Theuer CP, George DJ, Rini BI: Activity of SU11248, a
multitargeted inhibitor of vascular endothelial growth factor
receptor and platelet-derived growth factor receptor, in
patients with metastatic renal cell carcinoma. J Clin Oncol 2006,
24:16-24.
F1000 Factor 6.0 Must Read
Evaluated by Robert Dreicer 20 Jan 2006
6. Motzer R, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM,
Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW,
Baum CM, Figlin RA: Sunitinib versus interferon alfa in
metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-24.
F1000 Factor 9.0 Exceptional
Evaluated by Cora Sternberg 23 Jul 2007
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM,
Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-
Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST,
Chen I, Huang X, Figlin RA: Overall survival and updated results
Page 2 of 3
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:90 http://F1000.com/Reports/Medicine/content/1/90for sunitinib compared with interferon alfa in patients with
metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-90.
8. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M,
Bukowski RM: Randomized Phase III trial of the Raf kinase
and VEGFR inhibitor sorafenib (BAY 43-9006) in patients
with advanced renal cell carcinoma (RCC). J Clin Oncol 2005,
(June 1 Suppl):4510.
9. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M,
Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S,
Bukowski RM: Randomized phase II trial of first-line treat-
ment with sorafenib versus interferon Alfa-2a in patients
with metastatic renal cell carcinoma. J Clin Oncol 2009,
27:1280-289.
Changes Clinical Practice
F1000 Factor 3.0 Recommended
Evaluated by David M Nanus 04 Mar 2009
10. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R,
Cihon F, Anderson S, Shah S, Bukowski R, Escudier B: Sorafenib for
older patients with renal cell carcinoma: subset analysis from
a randomized trial. JNCI 2008, 100:1454-63.
11. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S,
Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G,
Berg WJ, Kay A, Lebwohl D, Ravaud A: Efficacy of everolimus in
advanced renal cell carcinoma: a double-blind, randomised,
placebo-controlled phase III trial. Lancet 2008, 372:449-56.
Changes Clinical Practice
F1000 Factor 6.5 Must Read
Evaluated by Karl-Dietrich Sievert 11 Jun 2009, Joaquim Bellmunt
02 Sep 2008, David M Nanus 20 Nov 2008
12. Hudes G, Carducci M, Tomczak P, Dutcher J, Riglin R, Kapoor A,
Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z,
Lesovoy V, Schmidt-Wolf I, Barbarash O, Gokmen E, O’Toole T,
Lustgarten S, Moore L, Motzer R: Temsirolimus, interferon alfa,
or both for advanced renal-cell carcinoma. N Engl J Med 2007,
356:2271-81.
Changes Clinical Practice
F1000 Factor 6.0 Must Read
Evaluated by Shahrokh Shariat 13 Aug 2008
13. Rini BI: Metastatic renal cell carcinoma: many treatment
options, one patient. J Clin Oncol 2009, 27:3225-34.
14. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA,
Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E,
Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA,
Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN,
Schwartz LH, Sheinfeld J, Wang J: NCCN clinical practice
guidelines in oncology: kidney cancer. J Natl Compr Canc Netw
2009, 7:618-30.
Page 3 of 3
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:90 http://F1000.com/Reports/Medicine/content/1/90
23